Posted 26th November 2019 by Joshua Sewell
The 4th Medicinal Chemistry & Protein Degradation Summit provided two days of fascinating topics and case studies about AI-assisted lead optimisation, DNA encoded libraries and the use of data and informatics in drug-discovery. We have made the following presentation slides available from Greg Makara, Paul Colbon and Yugal Sharma.
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Posted 30th September 2019 by Joshua Sewell
Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.
Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.
Posted 16th September 2019 by Liv Sewell
We spoke to John Griffin, CSO at Numerate, to find out how AI is changing drug discovery and development. Numerate is a drug design company applying cutting-edge AI to transform the process of small molecule drug design.
Posted 19th August 2019 by Jane Williams
e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.
Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.
Posted 17th June 2019 by Joshua Sewell
Flow cytometry is a powerful tool in drug discovery because it provides a way to understand the drug’s mechanism of action. In order to stratify a better target for patients, you often need to know where the drug is working, and what kind of pathway it is operating along.
Posted 14th November 2018 by Jane Williams
Droplet-based microfluidics is a technology that allows for the manipulation of small liquid droplets with a volume ranging from microliters to picolitres. The technology that handles discrete droplets is called digital microfluidics. The small volume offers various advantages such as quick mixing, simple handling, high throughput with a large number of droplets. The small volume also poses a serious challenge to engineering droplet-based microfluidic platforms: evaporation.